{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:39:58Z","timestamp":1767868798228,"version":"3.49.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with chronic lymphocytic leukemia (CLL) are highly vulnerable to infections owing to persistent immune dysfunction, leading to an increased risk of severe disease and reinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 210 CLL patients managed at the Hematology Unit, Sapienza University of Rome, who survived an initial SARS-CoV-2 infection between March 2020 and December 2024. The aim of this study was to assess the incidence, clinical course, and predictors of subsequent COVID-19 events during the Omicron-dominant period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A subsequent COVID-19 occurred in 71 patients (33.8%), diagnosed after a median of 14 months (IQR, 9\u201320) from the first episode. Reinfections were significantly more frequent in patients who had experienced their first infection before the Omicron wave (47% vs. 30%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.039). Compared with the initial event, subsequent COVID-19 was milder, with lower rates of pneumonia (8.4% vs. 22.7%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008), hospitalization (8.4% vs. 25.4%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), and no COVID-19\u2013related deaths. Patients on active CLL treatment and those with a Cumulative Illness Rating Scale score \u22656 were at significantly higher risk of reinfection. In multivariate analysis, ongoing CLL therapy (HR 1.92; 95% CI: 1.17\u20133.16;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.010) and elevated comorbidity burden (HR 2.20; 95% CI: 1.30\u20133.71;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003) independently predicted reinfection. SARS-CoV-2 vaccination did not significantly prevent new infections (36% vs. 33%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.638), but booster doses were associated with prolonged reinfection-free survival (16.3 vs. 9.3 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001). These findings indicate that SARS-CoV-2 reinfections remain common but generally mild among CLL patients in the Omicron era. High comorbidity burden and active therapy increase reinfection risk, while booster vaccination may extend protection intervals. Vaccination boosters are essential to reduce COVID-19 morbidity in this immunocompromised population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1737446","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:35Z","timestamp":1767849095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Sara","family":"Pepe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costanza","family":"Andriola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Sforzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01030-2","article-title":"Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia","volume":"34","author":"Roeker","year":"2020","journal-title":"Leukemia."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112993","article-title":"Antibody response to the SARS-coV-2 vaccine and COVID-19 vulnerability during the omicron pandemic in patients with CLL: two-year follow-up of a multicenter study","volume":"15","author":"Mauro","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2086249","article-title":"Characteristics of SARS-CoV-2 infection in lymphoma\/chronic lymphocytic leukemia patients during the Omicron outbreak","volume":"63","author":"Kohn","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e012328","DOI":"10.1136\/bmjgh-2023-012328","article-title":"Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis","volume":"8","author":"Relan","year":"2023","journal-title":"BMJ Glob Health"},{"key":"B9","unstructured":"Severity of disease associated with omicron variant as compared with delta variant in hospitalized patients with suspected or confirmed SARS-coV-2 infection"},{"key":"B10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological Malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.015","article-title":"COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge","volume":"40","author":"Bronstein","year":"2022","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"102553","DOI":"10.1016\/j.eclinm.2024","article-title":"Decoding the historical tale: COVID-19 impact on haematological Malignancy patients-EPICOVIDEHA insights from 2020 to 2022","volume":"71","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"EClinicalMedicine."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000522436","article-title":"COVID-19 in patients with hematologic Malignancies: outcomes and options for treatments","volume":"145","author":"Mart\u00ednez","year":"2022","journal-title":"Acta Haematol"},{"key":"B15","unstructured":"Emergency Committee on the COVID-19 pandemic\n          \n          2005"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2211055","article-title":"Immune imprinting and protection against repeat reinfection with SARS-coV-2","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.05.017","article-title":"Characteristics and clinical outcomes of patients with COVID-19 recurrent infection during the omicron variant predominance","volume":"114","author":"Abuhasira","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.15.04032","article-title":"Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis","volume":"15","author":"Kulkarni","year":"2025","journal-title":"J Glob Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood."},{"key":"B20","unstructured":""},{"key":"B21","unstructured":""},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106233","article-title":"Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological Malignancies","volume":"89","author":"Li","year":"2024","journal-title":"J Infect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27093","article-title":"The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL","volume":"98","author":"Visentin","year":"2023","journal-title":"Am J Hematol"},{"key":"B24","unstructured":""},{"key":"B25","unstructured":""},{"key":"B26","unstructured":""},{"key":"B27","unstructured":""},{"key":"B28","unstructured":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13878","article-title":"Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL","volume":"110","author":"Benjamini","year":"2023","journal-title":"Eur J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27218","article-title":"Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL","volume":"99","author":"Campanella","year":"2024","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.011","article-title":"Efficacy of multiple SARS-coV-2 vaccine doses in patients with B cell hematologic Malignancies receiving chimeric antigen receptor T cell therapy: A contemporary cohort analysis","volume":"30","author":"Abid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e252020","DOI":"10.1001\/jamaoncol.2025.2020","article-title":"COVID-19 vaccine booster uptake and effectiveness among US adults with cancer","volume":"2025","author":"Skarbinski","year":"2025","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00008-0","article-title":"A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial","volume":"12","author":"Cook","year":"2025","journal-title":"Lancet Haematol"},{"key":"B35","unstructured":"Fort Washington, PA\n          National Comprehensive Cancer Network\n          NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2026\n          \n          2025"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjh.70100","article-title":"2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia","author":"Walewska","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1737446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:36Z","timestamp":1767849096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1737446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":36,"alternative-id":["10.3389\/fonc.2025.1737446"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1737446","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1737446"}}